EMA Opens Biosimilars Guidelines for Comments - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Opens Biosimilars Guidelines for Comments



On May 31, 2012, EMA released a revised guideline to help the industry better address quality control of biosimilar drugs. The revision document, Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (Rev. 1), serves as an update to the association’s 2006 biosimilars guideline of the same name, which covered the molecular characteristics and quality assurance of a biosimilars compound. The 2006 document also addressed the performance and consistency of the manufacturing process of the biosimilar on its own.

The revised guideline provides more detail on how biosimilars manufacturers should compare their proposed compounds to those drugs already on the market. The guideline states that the purity and impurity profiles of drugs and APIs should be compared both qualitatively and quantitatively using state-of-the-art and orthogonal methods.

The EMA revision goes a bit further than the 2006 guideline to provide industry with more detail on comparability exercises for quality, considerations for reference drug products, analytical methods, physicochemical characterization, biological activity, and purity and quality attributes for relevant specifications of the biosimilar.

Comments on the revised guideline are due by the end of November 2012 and can be sent to bwp.biosimilar.revision@ema.europa.eu.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here